Trv Gp V LLC Makes New Investment in Maze Therapeutics, Inc. $MAZE

Trv Gp V LLC purchased a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 950,800 shares of the company’s stock, valued at approximately $28,371,872,000. Maze Therapeutics comprises approximately 5.7% of Trv Gp V LLC’s investment portfolio, making the stock its 3rd largest holding.

A number of other institutional investors also recently modified their holdings of MAZE. TRV GP IV LLC acquired a new stake in shares of Maze Therapeutics in the second quarter worth $133,502,907,000. BlackRock Inc. acquired a new position in Maze Therapeutics in the 2nd quarter valued at $104,525,000. Janus Henderson Group PLC raised its holdings in Maze Therapeutics by 318.0% in the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after acquiring an additional 2,390,713 shares during the period. Vanguard Group Inc. boosted its holdings in Maze Therapeutics by 27.1% during the fourth quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock valued at $70,307,000 after acquiring an additional 362,060 shares during the period. Finally, Alphabet Inc. acquired a new stake in shares of Maze Therapeutics in the second quarter valued at about $41,435,000.

Maze Therapeutics Price Performance

NASDAQ:MAZE opened at $29.13 on Wednesday. The stock has a market cap of $1.62 billion, a P/E ratio of -11.56 and a beta of 2.22. Maze Therapeutics, Inc. has a one year low of $12.81 and a one year high of $53.65. The company has a fifty day moving average price of $27.98 and a 200 day moving average price of $32.73. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.76). Analysts anticipate that Maze Therapeutics, Inc. will post -2.71 earnings per share for the current year.

Insider Activity at Maze Therapeutics

In related news, CEO Jason V. Coloma sold 34,501 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the transaction, the chief executive officer directly owned 23,337 shares in the company, valued at $699,643.26. The trade was a 59.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total value of $205,050.00. Following the completion of the transaction, the insider directly owned 26,250 shares of the company’s stock, valued at approximately $717,675. This trade represents a 22.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 140,674 shares of company stock worth $3,904,707. Company insiders own 5.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on MAZE. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Maze Therapeutics has an average rating of “Buy” and a consensus target price of $66.00.

Maze Therapeutics Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.